INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

Showing studies that examined garlic. Clear

People assigned to a diet, food or program and measured.

2 studies

2012 / Randomized controlled trial

Garlic reduced blood lead and symptoms similarly to d-penicillamine with fewer side effects

A randomized trial in 117 car battery industry workers evaluated garlic (1200 μg allicin three times daily) versus d-penicillamine (250 mg three times daily) for four weeks. Blood lead concentrations dropped significantly in both the garlic group (426.32 to 347.34 μg/L, p=0.002) and d-penicillamine group (417.47 to 315.76 μg/L, p=0.025), without differing significantly between groups. Garlic also improved symptoms such as headaches, irritability, deep tendon reflexes, and systolic blood pressure, while causing significantly fewer side effects than d-penicillamine (p=0.023).

Kianoush S, Balali-Mood M, Mousavi SR, et al. Basic Clin Pharmacol Toxicol, 2012. PMID 22151785

1993 / Randomized controlled trial

A 12-week regimen of garlic powder tablets increased walking distance in patients with stage II peripheral arterial occlusive disease.

Patients with stage II peripheral arterial occlusive disease received either 800 mg of garlic powder daily or a placebo for 12 weeks, with both groups undergoing physical therapy twice weekly. The increase in walking distance was significantly higher (P < 0.05) in the garlic group (by 46 m, from 161.0 +/- 65.1 to 207.1 +/- 85.0 m) compared with the placebo group (by 31 m, from 172.0 +/- 60.9 to 203.1 +/- 72.8 m). Diastolic blood pressure, spontaneous thrombocyte aggregation, plasma viscosity, and cholesterol concentration also decreased significantly, while body weight was maintained. The garlic-specific increase in walking distance did not appear until the 5th week of treatment, coinciding with a decrease in spontaneous thrombocyte aggregation.

Kiesewetter H, Jung F, Jung EM, et al. Clin Investig, 1993. PMID 8508009